MAPT and Alzheimer disease: In the present study, we evaluated the ability of the Janssen plasma p217+tau Simoa® assay to discriminate between AD disease stages, employing the biological PET stages recommended by the Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease (2024)10.